Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. - Wikidata - wikimedia - TriplyDB

Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

http://www.wikidata.org/entity/Q37361955

about

Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043.Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux Maximizing bactericidal activity with combinations of bioreduced drugs.Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.A three-dimensional chemical phase pharmacophore mapping, QSAR modelling and electronic feature analysis of benzofuran salicylic acid derivatives as LYP inhibitors.Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.

P2860

Q28539526-E07A970E-5FAD-40E0-99D5-EFACF66F762E Q35086722-ADFB1D5A-6F7F-4CEA-8264-FFD742A0D995 Q36270721-39C64976-61EC-487D-B7C1-DC72C75797D5 Q36393640-458E5CB9-376E-4FE3-A76E-E92F3EEB3476 Q36684151-8E6D0D60-FD6A-4960-A458-121D993C5ACE Q36934552-596F93FE-637F-4A12-898E-F5DA4579CBD4 Q37001484-97A0490A-07E7-4295-AB9E-C70C3070BD27 Q37679508-DE653D49-3CDA-4B4C-B69F-FE3FF4AB01BD Q39769351-EE531FF1-C140-44B8-BCDB-DCCAACD49300 Q43226839-F5B9E06E-5A69-46E8-862E-2EFC3DF19024 Q47306187-A0A4FE26-ED23-44CE-A1B6-D86CF4879768 Q47677066-AD47B1D6-0D3B-4B9E-A0EE-6A7BE9DAB832 Q54346229-970C7939-0004-4D90-ABDE-FD63F13F0C36

P2860

Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

http://www.wikidata.org/entity/Q37361955

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@en

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@nl

type

label

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@en

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@nl

prefLabel

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@en

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@nl

P1433

Q37361955-F89CCF14-63DE-4735-940D-F776430CD3D3

P1476

Q37361955-23768084-BC34-466C-AA78-BEE20D8B0311

P2093

Q37361955-0E009F9A-58C4-4279-8613-1D26A6BB7AA9

Q37361955-337B3F7B-F9DC-4185-B308-2FB1E7990291

Q37361955-41BF521C-BE01-481D-AEA9-ED9224ABB769

Q37361955-9DDAAB89-9FEE-4204-86A6-A8D98A934C6A

Q37361955-B1D8069A-5CAE-48F0-BA10-0266FC8E9355

Q37361955-D55AF7A5-FCF1-4E7D-BD69-BBE9D4D9B17B

P2860

Q37361955-046E6D33-BE98-4D40-9CB3-28EA16322697

Q37361955-215F7E98-489A-410C-BD17-02A5D96CA6D6

Q37361955-3A9089EF-D710-4C34-AA96-96CE1C435EF2

Q37361955-50371B47-D721-481F-B7BA-65E753A7D521

Q37361955-5D4C5B22-4208-4AF2-8D93-440DB9BD0A18

Q37361955-756439AE-0302-4D5D-B176-2BFBE9902E6C

Q37361955-91017A50-1668-430E-870C-C30CA6FED88C

Q37361955-9B58CF6C-0140-4C2C-B3DC-9D2A3CDF6317

Q37361955-9FE755A6-6C67-4921-9AA5-A17A4F834095

Q37361955-A51B6245-0742-4B26-97DE-E5D4E380005B

P2888

Q37361955-7DD1B858-32D3-4D89-A23D-D109EBFEDF02

P304

Q37361955-C14FB14E-9D0F-45E6-944C-0ABA83D40752

P31

Q37361955-829B7108-E982-4C40-A0C0-66AD37BB4DC1

P356

Q37361955-5AB7E45D-7AD8-40C9-AE5D-F5AEDC49500F

P407

Q37361955-4D9982BC-C45A-49D2-8679-6C7398755BA7

P433

Q37361955-5B08C1BB-2F0F-44ED-9F16-814B1675283B

P478

Q37361955-01D778F0-2E1F-4E1F-BF6E-EE343A18C40B

P50

Q37361955-B337B2F1-8CF5-487F-A38E-5F543B830FCF

Q37361955-D2DF171B-A379-4901-8C8B-BFE56F406856

P577

Q37361955-7C991005-3B48-4890-B8FC-0D0B7AA3D76D

P5875

Q37361955-3983E80E-870D-4087-ACF1-840C54B39989

P6179

Q37361955-A47F5A65-6C3A-4501-BB74-D83C5840016E

P698

Q37361955-83F14F17-4476-4307-8D25-305E24C051B2

P921

Q37361955-3DB3ED7D-71D3-4414-9047-E3355AA0000E

P932

Q37361955-7A209F14-BB7A-43AD-97E7-9AEE9E6E8AEF

P356

S12248-008-9017-8

P1433

The AAPS Journal

P1476

Pharmacokinetically-guided lea ...... mide anti-tuberculosis agents.

@en

P2093

Antwan J Daniels

http://www.w3.org/2001/XMLSchema#string

Jianjun Qi

http://www.w3.org/2001/XMLSchema#string

Nageshwar R Budha

http://www.w3.org/2001/XMLSchema#string

Nitin Mehrotra

http://www.w3.org/2001/XMLSchema#string

Rajendra Tangallapally

http://www.w3.org/2001/XMLSchema#string

Rakesh

http://www.w3.org/2001/XMLSchema#string

P2860

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Drug-like properties and the causes of poor solubility and poor permeability.

Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents.

Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation.

High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.

Optimization of metabolic stability as a goal of modern drug design.

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.

Solubilizing excipients in oral and injectable formulations.

P2888

s12248-008-9017-8

P304

157-165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-008-9017-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5404963

http://www.w3.org/2001/XMLSchema#string

P6179

1047498835

http://www.w3.org/2001/XMLSchema#string

P698

18446516

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2751462

http://www.w3.org/2001/XMLSchema#string